vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and Plymouth Industrial REIT, Inc. (PLYM). Click either name above to swap in a different company.

Plymouth Industrial REIT, Inc. is the larger business by last-quarter revenue ($51.2M vs $38.3M, roughly 1.3× ImmunityBio, Inc.). Plymouth Industrial REIT, Inc. runs the higher net margin — -106.3% vs -161.8%, a 55.5% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -1.4%).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Plymouth Industrial REIT, Inc. is a real estate investment trust focused on owning, operating, and acquiring high-quality industrial properties including distribution centers, warehouses, and light industrial facilities across key U.S. logistics hubs. It serves tenants in e-commerce, retail, manufacturing, and third-party logistics sectors, supporting diverse business supply chain needs.

IBRX vs PLYM — Head-to-Head

Bigger by revenue
PLYM
PLYM
1.3× larger
PLYM
$51.2M
$38.3M
IBRX
Growing faster (revenue YoY)
IBRX
IBRX
+408.3% gap
IBRX
407.0%
-1.4%
PLYM
Higher net margin
PLYM
PLYM
55.5% more per $
PLYM
-106.3%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
IBRX
IBRX
PLYM
PLYM
Revenue
$38.3M
$51.2M
Net Profit
$-61.9M
$-54.4M
Gross Margin
99.0%
Operating Margin
-169.0%
-102.5%
Net Margin
-161.8%
-106.3%
Revenue YoY
407.0%
-1.4%
Net Profit YoY
-4.7%
-248.5%
EPS (diluted)
$-0.06
$-1.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
PLYM
PLYM
Q4 25
$38.3M
Q3 25
$32.1M
$51.2M
Q2 25
$26.4M
$47.2M
Q1 25
$16.5M
$45.6M
Q4 24
$7.6M
$47.6M
Q3 24
$6.1M
$51.9M
Q2 24
$48.7M
Q1 24
$50.2M
Net Profit
IBRX
IBRX
PLYM
PLYM
Q4 25
$-61.9M
Q3 25
$-67.3M
$-54.4M
Q2 25
$-92.6M
$-6.1M
Q1 25
$-129.6M
$5.8M
Q4 24
$-59.2M
$147.4M
Q3 24
$-85.7M
$-15.6M
Q2 24
$1.3M
Q1 24
$6.2M
Gross Margin
IBRX
IBRX
PLYM
PLYM
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
IBRX
IBRX
PLYM
PLYM
Q4 25
-169.0%
Q3 25
-173.5%
-102.5%
Q2 25
-269.8%
-10.3%
Q1 25
-390.1%
Q4 24
-919.0%
Q3 24
-1314.3%
-29.6%
Q2 24
2.7%
Q1 24
Net Margin
IBRX
IBRX
PLYM
PLYM
Q4 25
-161.8%
Q3 25
-209.8%
-106.3%
Q2 25
-350.3%
-12.9%
Q1 25
-784.9%
12.8%
Q4 24
-783.4%
309.9%
Q3 24
-1404.0%
-30.1%
Q2 24
2.7%
Q1 24
12.4%
EPS (diluted)
IBRX
IBRX
PLYM
PLYM
Q4 25
$-0.06
Q3 25
$-0.07
$-1.23
Q2 25
$-0.10
$-0.14
Q1 25
$-0.15
$0.13
Q4 24
$-0.08
$3.24
Q3 24
$-0.14
$-0.35
Q2 24
$0.03
Q1 24
$0.14

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
PLYM
PLYM
Cash + ST InvestmentsLiquidity on hand
$242.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-500.5M
$470.1M
Total Assets
$501.9M
$1.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
PLYM
PLYM
Q4 25
$242.8M
Q3 25
$257.8M
Q2 25
$153.7M
Q1 25
$61.6M
Q4 24
$149.8M
Q3 24
$130.4M
Q2 24
Q1 24
Total Debt
IBRX
IBRX
PLYM
PLYM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$646.4M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IBRX
IBRX
PLYM
PLYM
Q4 25
$-500.5M
Q3 25
$-524.3M
$470.1M
Q2 25
$-570.7M
$539.6M
Q1 25
$-591.4M
$571.0M
Q4 24
$-489.1M
$579.5M
Q3 24
$-745.1M
$436.5M
Q2 24
$475.2M
Q1 24
$484.6M
Total Assets
IBRX
IBRX
PLYM
PLYM
Q4 25
$501.9M
Q3 25
$519.0M
$1.6B
Q2 25
$402.1M
$1.6B
Q1 25
$303.8M
$1.4B
Q4 24
$382.9M
$1.4B
Q3 24
$364.6M
$1.5B
Q2 24
$1.4B
Q1 24
$1.4B
Debt / Equity
IBRX
IBRX
PLYM
PLYM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
1.12×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
PLYM
PLYM
Operating Cash FlowLast quarter
$-70.4M
$20.0M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
PLYM
PLYM
Q4 25
$-70.4M
Q3 25
$-68.9M
$20.0M
Q2 25
$-79.7M
$23.4M
Q1 25
$-85.9M
$15.6M
Q4 24
$-85.1M
$96.1M
Q3 24
$-98.8M
$17.6M
Q2 24
$19.9M
Q1 24
$16.6M
Free Cash Flow
IBRX
IBRX
PLYM
PLYM
Q4 25
$-71.3M
Q3 25
$-69.6M
Q2 25
$-80.8M
Q1 25
$-87.0M
Q4 24
$-87.3M
Q3 24
$-101.6M
Q2 24
Q1 24
FCF Margin
IBRX
IBRX
PLYM
PLYM
Q4 25
-186.2%
Q3 25
-217.2%
Q2 25
-305.9%
Q1 25
-526.9%
Q4 24
-1155.4%
Q3 24
-1663.2%
Q2 24
Q1 24
Capex Intensity
IBRX
IBRX
PLYM
PLYM
Q4 25
2.4%
Q3 25
2.3%
Q2 25
4.1%
Q1 25
6.8%
Q4 24
28.0%
Q3 24
45.7%
Q2 24
Q1 24
Cash Conversion
IBRX
IBRX
PLYM
PLYM
Q4 25
Q3 25
Q2 25
Q1 25
2.67×
Q4 24
0.65×
Q3 24
Q2 24
15.12×
Q1 24
2.67×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons